Other languages Sino Biopharmaceutical Limited

Equities

1177

KYG8167W1380

Delayed Hong Kong S.E. Other stock markets 09:29:59 29/04/2024 am IST			5-day change	1st Jan Change
2.86 ^HKD	+3.25%		+12.20%	-17.87%

25/04	Sino Biopharm Completes Phase I Study of Hepatitis B Drug	MT
22/04	Lull in Geopolitical Tensions Lifts Asian Stock Markets	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sino Biopharm Completes Phase I Study of Hepatitis B Drug	25/04
Lull in Geopolitical Tensions Lifts Asian Stock Markets	22/04
Hong Kong shares jump on policy support; China slips	22/04
Borse Cina : chiudono miste, in rialzo Hong Kong con decisione su tassi	22/04
Hong Kong shares jump 1.5% on policy support; China slips	22/04
Sino Biopharmaceutical Limited Announces Category 1 Innovative Drug Rovadicitinib Obtained Positive Results in Key Clinical Research for Registration	18/04
Sino Biopharmaceutical Trustee Repurchases Shares	08/04
Sino Biopharmaceutical to Develop Boehringer Ingelheim's Cancer Treatments in China	08/04
Sino Biopharmaceutical Limited Enters into Strategic Partnership with Boehringer Ingelheim on Innovative Oncology Portfolio in China	08/04
Sino Biopharmaceutical's Attributable Profit Drops 8.3% in 2023	29/03
Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024	28/03
Sino Biopharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Sino Biopharmaceutical's Diagnostic Agent Injection Gets Marketing Nod in China	25/03
Sino Biopharmaceutical Limited Announces Approval for Marketing of Iopromide Injection	25/03
Sino Biopharmaceutical's Developing Two Drugs for MASH	15/03
Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"	15/03
Sino Biopharmaceutical to Present Cancer Drug Phase II Trial Findings at 2024 AACR	14/03
Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet	13/03
Hong Kong Shares Slump Amid Chinese Growth Concerns	05/03
Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart	28/02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Sino Biopharmaceutical Limited

Equities

1177

KYG8167W1380

Other languages

Filters